Opinion

Video

Anticipating Key Studies and Pipeline Treatments in mCRC Landscape

Author(s):

Aparna R. Parikh, MDMarwan G. Fakih, MD

The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.

Related Videos
5 KOLs are featured in this program
5 KOLs are featured in this program
A panel of 4 experts on lung cancer
A panel of 4 experts on lung cancer
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
A panel of 5 experts on breast cancer
5 KOLs are featured in this peer exchange
Tycel Phillips, MD
5 KOLs are featured in this panel.
Related Content
Richard Kim, MD
July 19th 2024

Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC

Martin F. Dietrich, MD, PhD, medical oncologist, Cancer Care Centers of Brevard, The US Oncology Network, assistant professor, internal medicine, the University of Central Florida College of Medicine; Michelle Shiller, DO, cancer liaison physician, medical director, Genetics, assistant medical director, Baylor Scott & White Health in Dallas, medical director, Genomics and Molecular Pathology Services, PathGroup
June 27th 2024

Dietrich and Shiller Dive Into the Importance of Oncology Reflex Testing

Botensilimab/Baltstilimab in MSS CRC | Image Credit: © Dr_Microbe - stock.adobe.com
July 18th 2024

FDA Advises Against Accelerated Approval Pathway for Botensilimab/Balstilimab in R/R MSS CRC

Heinz-Josef Lenz, MD, FACP, about the prognostic and predictive value of HER2 gene expression for patients with KRAS wild-type metastatic colorectal cancer (mCRC). Lenz is a professor in the Department of Medicine and the Department of Preventive Medicine in the Division of Oncology at the University of Southern California (USC) Keck School of Medicine in Los Angeles. He also serves as the associate director of Clinical Research, chair of the Gastrointestinal Oncology Program, and co-director of the Colorectal Center at the USC Norris Comprehensive Cancer Center
June 3rd 2024

Lenz Discusses the Prognostic and Predictive Value of HER2 Gene Expression in KRAS Wild-Type mCRC

Saul Priceman, PhD, of City of Hope
July 15th 2024

City of Hope CAR T-Cell Therapy for Advanced Prostate Cancer Demonstrates Positive Results in Phase 1 Clinical Trial

Tycel Phillips, MD, associate professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
July 10th 2024

Phillips Discusses Past Progress and Previews the Future in Hematologic Cancers